ALLURION TECHNOLOGIES, INC.
NYSE: ALUR (Allurion Technologies, Inc.)
Last update: 4 hours ago2.02
0.03 (1.76%)
| Previous Close | 1.99 |
| Open | 1.97 |
| Volume | 32,801 |
| Avg. Volume (3M) | 56,376 |
| Market Cap | 15,680,615 |
| Price / Earnings (Forward) | 1.00 |
| Price / Sales | 0.450 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Profit Margin | -86.05% |
| Operating Margin (TTM) | -130.50% |
| Diluted EPS (TTM) | -14.22 |
| Quarterly Revenue Growth (YOY) | -40.50% |
| Quarterly Earnings Growth (YOY) | 32.10% |
| Current Ratio (MRQ) | 2.09 |
| Operating Cash Flow (TTM) | -43.13 M |
| Levered Free Cash Flow (TTM) | -20.05 M |
| Return on Assets (TTM) | -52.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Allurion Technologies, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 0.33 |
|
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 11.67% |
| % Held by Institutions | 46.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rtw Investments, Lp | 30 Jun 2025 | 2,542,603 |
| Unisphere Establishment | 30 Jun 2025 | 49,695 |
| Xtx Topco Ltd | 30 Jun 2025 | 18,670 |
| Caas Capital Management Lp | 31 Mar 2025 | 10,950 |
| Lri Investments, Llc | 30 Jun 2025 | 8,185 |
| Centerpoint Advisors, Llc | 30 Jun 2025 | 6,347 |
| Tower Research Capital Llc (Trc) | 30 Jun 2025 | 2,262 |
| Citigroup Inc | 30 Jun 2025 | 1,679 |
| Osaic Holdings, Inc. | 30 Jun 2025 | 790 |
| Group One Trading Llc | 30 Jun 2025 | 199 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Oct 2025 | Announcement | Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss |
| 30 Sep 2025 | Announcement | Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference |
| 13 Aug 2025 | Announcement | Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 07 Aug 2025 | Announcement | Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025 |
| 22 Jul 2025 | Announcement | Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |